Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is -19.91% lower on its value in year-to-date trading and has touched a low of $4.71 and a high of $10.05 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUPH stock was last observed hovering at around $7.20 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $7.20, the stock is 5.02% and 16.87% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.97 million and changing 0.00% at the moment leaves the stock 13.94% off its SMA200. AUPH registered -13.67% loss for a year compared to 6-month gain of 43.71%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 9.26% loss in the last 1 month and extending the period to 3 months gives it a 30.20%, and is 2.42% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.76% over the week and 4.73% over the month.
Aurinia Pharmaceuticals Inc (AUPH) has around 300 employees, a market worth around $1.03B and $207.11M in sales. Fwd P/E is 17.28. Profit margin for the company is -24.31%. Distance from 52-week low is 52.87% and -28.36% from its 52-week high. The company has generated returns on investments over the last 12 months (-11.56%).
with sales reaching $56.09M over the same period.The EPS is expected to grow by 108.95% this year, but quarterly earnings will post 33.40% year-over-year. Quarterly sales are estimated to grow 2.90% in year-over-year returns.
Aurinia Pharmaceuticals Inc (AUPH) Top Institutional Holders
244.0 institutions hold shares in Aurinia Pharmaceuticals Inc (AUPH), with institutional investors hold 47.05% of the company’s shares. The shares outstanding are 143.83M, and float is at 128.68M with Short Float at 6.77%. Institutions hold 43.72% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 11.14 million shares valued at $63.59 million. The investor’s holdings represent 7.7326% of the AUPH Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.27 million shares valued at $52.94 million to account for 6.4384 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 3.97 million shares representing 2.7566% and valued at over $22.67 million, while STATE STREET CORP holds 1.9999 of the shares totaling 2.88 million with a market value of $16.45 million.
Aurinia Pharmaceuticals Inc (AUPH) Insider Activity
The most recent transaction is an insider sale by Habig Scott Michael, the company’s Chief Commercial Officer. SEC filings show that Habig Scott Michael sold 18,249 shares of the company’s common stock on Aug 06 ’24 at a price of $5.31 per share for a total of $96902.0. Following the sale, the insider now owns 0.46 million shares.
Aurinia Pharmaceuticals Inc disclosed in a document filed with the SEC on May 21 ’24 that Balakrishnan Brinda (Director) sold a total of 520 shares of the company’s common stock. The trade occurred on May 21 ’24 and was made at $5.74 per share for $2985.0. Following the transaction, the insider now directly holds 17523.0 shares of the AUPH stock.
Still, SEC filings show that on May 21 ’24, Billen Daniel (Director) disposed off 5,252 shares at an average price of $5.74 for $30146.0. The insider now directly holds 28,141 shares of Aurinia Pharmaceuticals Inc (AUPH).
